Skip to main content
News

Pimicotinib Achieves 76% Response Rate With Durable Clinical Benefit in Tenosynovial Giant Cell Tumor

Edited by 

Clinical Summary: 

  • Design/Population: The phase 3 MANEUVER trial evaluated pimicotinib, an oral CSF-1R inhibitor, in patients with symptomatic tenosynovial giant cell tumor (TGCT) eligible for systemic treatment. This 2-year follow-up analysis assessed long-term tumor responses, symptom improvement, physical function, and safety among patients initially randomized to pimicotinib.

  • Key Outcomes: Improvements in pain, stiffness, range of motion, and physical function were sustained through 2 years. The objective response rate (ORR) was 76.2% by RECIST version 1.1, while the tumor volume score-based ORR increased to 77.8%. Median duration of response was not reached, and no new safety findings were reported.

  • Clinical Relevance: These findings support the durability of clinical benefit with pimicotinib in TGCT, demonstrating sustained tumor control and improvements in symptoms and joint function that may reduce the long-term burden of disease.

Updated 2-year results from the phase 3 MANEUVER trial demonstrated sustained improvements in pain, stiffness, range of motion, and physical function with pimicotinib in patients with tenosynovial giant cell tumor (TGCT), alongside durable tumor responses and a safety profile consistent with previous analyses.

In this double-blind, placebo-controlled trial, 94 patients with TGCT who were eligible for systemic therapy and had not previously received anti-CSF-1 or anti-CSF-1R treatment were randomized 2:1 to receive either 50 mg of once daily pimicotinib (n = 63) or placebo (n = 31) for 24 weeks.

The primary end point was objective response rate (ORR) at week 25, assessed by blinded independent central review according to RECIST version 1.1. Key secondary end points included tumor volume score, range of motion, stiffness, pain, and physical function.

Following the double-blind treatment period, eligible patients from either treatment arm could enter an open-label phase and receive up to 24 additional weeks of pimicotinib. Patients completing this phase could continue into an open-label extension for longer-term treatment and safety follow-up.

The current analysis evaluated longer-term outcomes among patients initially randomized to pimicotinib, with a March 1, 2026, data cutoff.

Improvements in symptoms and joint function were observed as early as week 5 and were sustained through 2 years, with continued improvement over time.

At week 97, mean range of motion improved by 19.6% from baseline. Mean stiffness scores decreased by 3.9 points, as assessed by the Worst Stiffness Numeric Rating Scale, while mean pain scores decreased by 3.1 points according to the Brief Pain Inventory worst pain rating.

Physical function also improved, with a mean increase of 7.4 points from baseline on the Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS-PF) scale.

Tumor responses remained durable through 2 years. The ORR was 76.2%, unchanged from the 1-year analysis. The ORR based on tumor volume score increased from 74.6% at 1 year to 77.8% at 2 years.

Median duration of response had not been reached at the time of analysis. Median treatment duration was 22.6 months, ranging from 1.8 to 33.6 months. At 2 years, 54% of patients initially randomized to pimicotinib remained on treatment.

The safety profile of pimicotinib remained consistent with previous analyses, with no evidence of cholestatic hepatotoxicity or hair or skin hypopigmentation reported. During the randomized, double-blind treatment phase, treatment-emergent adverse events led to treatment discontinuation in 1 patient (1.6%) receiving pimicotinib, while dose reductions occurred in 5 patients (7.9%).

The investigators concluded that the 2-year MANEUVER findings demonstrate sustained tumor responses and improvements in symptoms and physical function with pimicotinib, supporting its potential to provide durable clinical benefit for patients with TGCT.


Source: 

EMD Serano. Two-year data of pimicotinib demonstrated durable tumor control and sustained improvement in TGCT symptoms and joint function. Accessed on: November 18, 2026. https://www.emdserono.com/us-en/company/news/press-releases/pimicotinib-two-year-data-10-26-2026.html 

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.